Your email has been successfully added to our mailing list.

×
-0.0963172804532578 -0.0963172804532578 -0.104815864022663 -0.093484419263456 -0.18413597733711 -0.371104815864023 -0.291784702549575 -0.206798866855524
Stock impact report

Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc (LXRX)  More Company Research Source: GlobeNewswire
Last lexicon pharmaceuticals, inc earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF THE WOODLANDS, Texas, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response Letter in relation to the New Drug Application for sotagliflozin (ZynquistaTM) in type 1 diabetes. Lexicon intends to appeal the decision to the Center for Drug Evaluation and Research, or CDER. Conference Call Information Lexicon management will hold a live conference call today, December 2, 2019, at 8:00 am EST / 7:00 am CST to discuss today’s announcement. The dial-in number for the conference call is 888-645-5785 (U.S./Canada) or 970-300-1531 (international). The conference ID for all callers is 1857906. The replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/investors and will be available on the website for 14 days. About Zynquista (sotagliflozin) [Read more]
Impact snapshot Event time: LXRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
LXRX alerts
from News Quantified
Opt-in for
LXRX alerts

from News Quantified
Opt-in for
LXRX alerts

from News Quantified